Zika Virus (ZIKV) belongs to the class of flavivirus that can be transmitted by Aedes mosquitoes. The number of Zika virus caused cases of acute infections, neurological disorders and congenital microcephaly are rapidly growing and therefore, in 2016, the World Health Organization declared a global “Public Health Emergency of International Concern”. Anti-ZIKV therapeutic and vaccine development strategies are growing worldwide in recent years, however, no specific and safe treatment is available till date to save the human life. Currently, development of peptide therapeutics against ZIKV has attracted rising attention on account of their high safety concern and low development cost, in comparison to small therapeutic molecules and antibody-based anti-viral drugs. In present review, an overview of ZIKV inhibition by peptide-based inhibitors including E-protein derived peptides, antimicrobial peptides, frog skin peptides and probiotic peptides has been discussed. Peptides inhibitors have also been reported to act against NS5, NS2B-NS3 protease and proteasome in order to inhibit ZIKV infection. Recent advances in peptide-based therapeutics and vaccine have been reviewed and their future promise against ZIKV infections has been explored.

寨卡病毒（ZIKV）属于可通过伊蚊传播的黄病毒。寨卡病毒引起的急性感染，神经系统疾病和先天性小头畸形病例迅速增加，因此，2016年，世界卫生组织宣布全球为“国际关注的突发公共卫生事件”。近年来，抗ZIKV的治疗和疫苗开发策略在全球范围内不断发展，但是，迄今为止，还没有任何具体，安全的治疗方法可以挽救人类的生命。当前，与小治疗分子和基于抗体的抗病毒药物相比，针对ZIKV的肽治疗剂的开发由于其高安全性和低开发成本而引起了越来越多的关注。在目前的评论中，讨论了基于肽的抑制剂对ZIKV的抑制作用，这些抑制剂包括E蛋白衍生肽，抗菌肽，蛙皮肽和益生菌肽。为了抑制ZIKV感染，也已经报道了肽抑制剂对NS5，NS2B-NS3蛋白酶和蛋白酶体起作用。综述了基于肽的治疗剂和疫苗的最新进展，并探讨了其针对ZIKV感染的未来前景。